ArticleFrontiers in endocrinology2025
Circulating prosaposin and ependymin-related protein 1 levels are correlated with insulin resistance in type 2 diabetic patients.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Adipose Tissue-Derived Small Extracellular Vesicles in Plasma Reveal Molecular Circuitries Underlying Glucose Intolerance.Obesity (Silver Spring, Md.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Skeletal muscle and adipose tissues secrete myokines and adipokines to regulate energy metabolism. Experimental evidence indicates that prosaposin (PSAP) and ependymin-related protein 1 (EPDR1) are involved in the regulation of thermogenesis and energy metabolism. To our knowledge, little literature has been found dealing with PSAP and EPDR1 levels in type 2 diabetes mellitus (T2DM) patients. The aim of the study was to evaluate possible relationships between both peptide levels and insulin resistance indexes in type 2 diabetic subjects. Methods: The study groups consisted of 64 T2DM subjects and 22 normal controls. Serum PSAP and EPDR1 concentrations were determined using immunosorbent assay kits. Results: The serum PSAP (319.6 ± 78.38 vs. 207.2 ± 42.43, P<0.0001) and EPDR1 (7.988 ± 3.484 vs. 6.399 ± 3.788, P=0.0823) concentrations were higher in T2DM subjects than normal controls. In addition, positive correlations were found between: PSAP and fasting blood glucose (FBG) levels (r = 0.5004; P< 0.0001), PSAP and Hemoglobin A1c (HAb1c) (r = 0.4688; P< 0.0001), PSAP and C-peptide (r = 0.3981; P = 0.0003), PSAP and triglyceride-glucose index (TyG) (r = 0.2362; P< 0.0001), PSAP and homeostasis model assessment of insulin resistance (HOMA-IR) (r = 0.3314; P = 0.0035), PSAP and homeostasis model assessment of C-peptide resistance (HOMA-CR) (r = 0.5486; P< 0.0001), EPDR1 and insulin (r = 0.2291; P = 0.045), EPDR1 and HOMA-IR (r = 0.2462; P = 0.0309) in both T2DM and normal control subjects. Conclusions: Our results indicated that T2DM individuals have higher serum PSAP and EPDR1 levels, and both peptide concentrations were positively correlative to insulin (INS) resistance levels. PSAP and EPDR1 levels may be taken as potential biomarkers to forecast the development of T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.